A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE).
Chee Khoon Lee, Shalini Subramaniam, Antony Mersiades, Jenna Mitchell, Hannora Jurkovic, Mariya Walker, Loc Le, Chris Brown, Benjamin J Solomon, Tom John, Martin R Stockler, Bin-Chi Liao, James Chih-Hsin Yang, Chao-Hua Chiu
Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2020
TPS9631 Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have proven remarkably effective in the treatment of advanced EGFR mutant non-small cell lung cancer (NSCLC). However, drug resistance is inevitable and outcomes with subsequent platinum-pemetrexed chemotherapy are poor. The role of immune-checkpoint inhibitor monotherapy in EGFR mutant NSCLC remains uncertain with trials demonstrating inferior survival outcomes compared to chemotherapy. However, a recent randomised study with combination checkpoint inhibitor-chemotherapy demonstrated improved survival over chemotherapy alone in this patient population. This study aims to evaluate the efficacy and ..View full abstract